Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why ...
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
1d
News Medical on MSNHigh discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
14h
News Medical on MSNGLP-1 drug exenatide shows no benefit for Parkinson's in new studyThe GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results